FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2078111654> ?p ?o ?g. }

• W2078111654 endingPage "106" @default.
• W2078111654 startingPage "100" @default.
• W2078111654 abstract "Summary. Recombinant activated factor VII (rFVIIa), licensed in 1999 for treatment of haemophilia patients with inhibitors (HI), represents an important advance in the therapeutic armamentarium. Standard bolus dosing ranges from 90 to 120 mcg kg −1 every 2–3 h until arrest of bleeding. As licensure, clinical use of rFVIIa has increased and broadened. Clinicians now use a wide dose range, 90–300 mcg kg −1 . High‐dose regimens may optimize thrombin generation or burst, and may allow for prolonged dose interval. The Hemophilia and Thrombosis Research Society (HTRS) maintains a registry database to study haemophilia treatment and related disorders, particularly treatment of acute bleeding in HI, acquired haemophilia, FVII deficiency and von Willebrand's disease (VWD). To assess the effect of rFVIIa dose on efficacy and safety in the treatment of acute bleeding in HI, data from the HTRS database from January 2000 through June 2002 were analysed. Bleeding episodes were grouped by bolus rFVIIa dose range: <100, 100–150, 150–200 and >200 mcg kg −1 . Investigator‐reported efficacy for the first 72 h of treatment was evaluated. Thirty‐eight congenital HI patients were treated for 555 bleeding episodes. Patient age range was 1–55 years (median: 14). Bleeding episodes were spontaneous (45%), caused by trauma (38%), or because of surgery, dental, diagnostic, or medical procedures (17%); bleeding occurred in joint, muscle, and intra/extracranial sites. Treatment location included: 80% at home, 12% at other facilities (treatment centres, ER, inpatient and OR), and 8% at both home/other facilities. Median total dose given over 72 h was 360 mcg kg −1 (range: 40–4281, mean: 537). Bleeding stopped in 87% of the episodes. Bleeding cessation rate was 84% for the three lower dose groups, and 97% for the highest dose group ( P < 0.001). Five patients experienced nine adverse events (AEs). AE rates were <1% for <100, 5% for 100–150, 0% for 150–200, <1% for >200 mcg kg −1 dose group. Decreased therapeutic response accounted for eight of the nine AEs. These data, which represent the most comprehensive report of rFVIIa use since the USA licensure, demonstrate that bleeding episodes in HI patients can be treated safely and effectively at home and that doses up to 346 mcg kg −1 appear to be well‐tolerated. Additionally, rFVIIa doses >200 mcg kg −1 appear to significantly increase efficacy (97% in the high‐dose group, compared with 84% in the lower dose groups). Optimal dosing remains to be determined; specifically, what the lowest effective dose is and whether a single high‐dose bolus eliminates the need for repeated dosing. Recombinant FVIIa appears to have a wide safety margin that may allow dose escalation to address these questions." @default.
• W2078111654 created "2016-06-24" @default.
• W2078111654 creator A5000877769 @default.
• W2078111654 creator A5013658598 @default.
• W2078111654 creator A5014530935 @default.
• W2078111654 creator A5019490847 @default.
• W2078111654 creator A5019518672 @default.
• W2078111654 creator A5020488137 @default.
• W2078111654 creator A5023583996 @default.
• W2078111654 creator A5031246149 @default.
• W2078111654 creator A5038396248 @default.
• W2078111654 creator A5038458868 @default.
• W2078111654 creator A5038597185 @default.
• W2078111654 creator A5042615535 @default.
• W2078111654 creator A5046974180 @default.
• W2078111654 creator A5050252054 @default.
• W2078111654 creator A5055123962 @default.
• W2078111654 creator A5057823441 @default.
• W2078111654 creator A5063823763 @default.
• W2078111654 creator A5066236327 @default.
• W2078111654 creator A5067096441 @default.
• W2078111654 creator A5071684654 @default.
• W2078111654 creator A5073647066 @default.
• W2078111654 creator A5078159824 @default.
• W2078111654 creator A5080512590 @default.
• W2078111654 creator A5083098212 @default.
• W2078111654 creator A5085157279 @default.
• W2078111654 creator A5090596896 @default.
• W2078111654 date "2005-03-01" @default.
• W2078111654 modified "2023-10-15" @default.
• W2078111654 title "Dose effect and efficacy of rFVIIa in the treatment of haemophilia patients with inhibitors: analysis from the Hemophilia and Thrombosis Research Society Registry" @default.
• W2078111654 cites W194949005 @default.
• W2078111654 cites W1964450296 @default.
• W2078111654 cites W1982381467 @default.
• W2078111654 cites W1993029546 @default.
• W2078111654 cites W1998000461 @default.
• W2078111654 cites W1998107565 @default.
• W2078111654 cites W2042508808 @default.
• W2078111654 cites W2046936517 @default.
• W2078111654 cites W2052867868 @default.
• W2078111654 cites W2069476835 @default.
• W2078111654 cites W2114591836 @default.
• W2078111654 cites W2148505112 @default.
• W2078111654 cites W2157140221 @default.
• W2078111654 cites W2158441938 @default.
• W2078111654 cites W2414916611 @default.
• W2078111654 cites W4231991843 @default.
• W2078111654 cites W4235116425 @default.
• W2078111654 doi "https://doi.org/10.1111/j.1365-2516.2005.01075.x" @default.
• W2078111654 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15810910" @default.
• W2078111654 hasPublicationYear "2005" @default.
• W2078111654 type Work @default.
• W2078111654 sameAs 2078111654 @default.
• W2078111654 citedByCount "159" @default.
• W2078111654 countsByYear W20781116542012 @default.
• W2078111654 countsByYear W20781116542013 @default.
• W2078111654 countsByYear W20781116542014 @default.
• W2078111654 countsByYear W20781116542015 @default.
• W2078111654 countsByYear W20781116542016 @default.
• W2078111654 countsByYear W20781116542017 @default.
• W2078111654 countsByYear W20781116542018 @default.
• W2078111654 countsByYear W20781116542019 @default.
• W2078111654 countsByYear W20781116542020 @default.
• W2078111654 countsByYear W20781116542022 @default.
• W2078111654 crossrefType "journal-article" @default.
• W2078111654 hasAuthorship W2078111654A5000877769 @default.
• W2078111654 hasAuthorship W2078111654A5013658598 @default.
• W2078111654 hasAuthorship W2078111654A5014530935 @default.
• W2078111654 hasAuthorship W2078111654A5019490847 @default.
• W2078111654 hasAuthorship W2078111654A5019518672 @default.
• W2078111654 hasAuthorship W2078111654A5020488137 @default.
• W2078111654 hasAuthorship W2078111654A5023583996 @default.
• W2078111654 hasAuthorship W2078111654A5031246149 @default.
• W2078111654 hasAuthorship W2078111654A5038396248 @default.
• W2078111654 hasAuthorship W2078111654A5038458868 @default.
• W2078111654 hasAuthorship W2078111654A5038597185 @default.
• W2078111654 hasAuthorship W2078111654A5042615535 @default.
• W2078111654 hasAuthorship W2078111654A5046974180 @default.
• W2078111654 hasAuthorship W2078111654A5050252054 @default.
• W2078111654 hasAuthorship W2078111654A5055123962 @default.
• W2078111654 hasAuthorship W2078111654A5057823441 @default.
• W2078111654 hasAuthorship W2078111654A5063823763 @default.
• W2078111654 hasAuthorship W2078111654A5066236327 @default.
• W2078111654 hasAuthorship W2078111654A5067096441 @default.
• W2078111654 hasAuthorship W2078111654A5071684654 @default.
• W2078111654 hasAuthorship W2078111654A5073647066 @default.
• W2078111654 hasAuthorship W2078111654A5078159824 @default.
• W2078111654 hasAuthorship W2078111654A5080512590 @default.
• W2078111654 hasAuthorship W2078111654A5083098212 @default.
• W2078111654 hasAuthorship W2078111654A5085157279 @default.
• W2078111654 hasAuthorship W2078111654A5090596896 @default.
• W2078111654 hasConcept C126322002 @default.
• W2078111654 hasConcept C141071460 @default.
• W2078111654 hasConcept C2777081929 @default.
• W2078111654 hasConcept C2777232031 @default.
• W2078111654 hasConcept C2777288759 @default.
• W2078111654 hasConcept C2778385053 @default.
• W2078111654 hasConcept C2778961111 @default.

• next